Clinical isolates of uncomplicated falciparum malaria from high and low malaria transmission areas show distinct pfcrt and pfmdr1 polymorphisms in western Ethiopia.
Humans
Antimalarials
/ pharmacology
Ethiopia
/ epidemiology
Artemether, Lumefantrine Drug Combination
/ therapeutic use
Artemether
/ therapeutic use
Malaria, Falciparum
/ parasitology
Chloroquine
/ pharmacology
Malaria
/ drug therapy
Lumefantrine
/ therapeutic use
Plasmodium falciparum
Polymorphism, Single Nucleotide
Multidrug Resistance-Associated Proteins
/ genetics
Protozoan Proteins
/ genetics
Drug Resistance
/ genetics
Pfcrt
Pfmdr1
Polymorphisms in a gradient of malaria transmission
Journal
Malaria journal
ISSN: 1475-2875
Titre abrégé: Malar J
Pays: England
ID NLM: 101139802
Informations de publication
Date de publication:
03 Jun 2023
03 Jun 2023
Historique:
received:
30
12
2022
accepted:
20
05
2023
medline:
5
6
2023
pubmed:
4
6
2023
entrez:
3
6
2023
Statut:
epublish
Résumé
Pfcrt gene has been associated with chloroquine resistance and the pfmdr1 gene can alter malaria parasite susceptibility to lumefantrine, mefloquine, and chloroquine. In the absence of chloroquine (CQ) and extensive use of artemether-lumefantrine (AL) from 2004 to 2020 to treat uncomplicated falciparum malaria, pfcrt haplotype, and pfmdr1 single nucleotide polymorphisms (SNPs) were determined in two sites of West Ethiopia with a gradient of malaria transmission. 230 microscopically confirmed P. falciparum isolates were collected from Assosa (high transmission area) and Gida Ayana (low transmission area) sites, of which 225 of them tested positive by PCR. High-Resolution Melting Assay (HRM) was used to determine the prevalence of pfcrt haplotypes and pfmdr1 SNPs. Furthermore, the pfmdr1 gene copy number (CNV) was determined using real-time PCR. A P-value of less or equal to 0.05 was considered significant. Of the 225 samples, 95.5%, 94.4%, 86.7%, 91.1%, and 94.2% were successfully genotyped with HRM for pfcrt haplotype, pfmdr1-86, pfmdr1-184, pfmdr1-1042 and pfmdr1-1246, respectively. The mutant pfcrt haplotypes were detected among 33.5% (52/155) and 80% (48/60) of isolates collected from the Assosa and Gida Ayana sites, respectively. Plasmodium falciparum with chloroquine-resistant haplotypes was more prevalent in the Gida Ayana area compared with the Assosa area (COR = 8.4, P = 0.00). Pfmdr1-N86Y wild type and 184F mutations were found in 79.8% (166/208) and 73.4% (146/199) samples, respectively. No single mutation was observed at the pfmdr1-1042 locus; however, 89.6% (190/212) of parasites in West Ethiopia carry the wild-type D1246Y variants. Eight pfmdr1 haplotypes at codons N86Y-Y184F-D1246Y were identified with the dominant NFD 61% (122/200). There was no difference in the distribution of pfmdr1 SNPs, haplotypes, and CNV between the two study sites (P > 0.05). Plasmodium falciparum with the pfcrt wild-type haplotype was prevalent in high malaria transmission site than in low transmission area. The NFD haplotype was the predominant haplotype of the N86Y-Y184F-D1246Y. A continuous investigation is needed to closely monitor the changes in the pfmdr1 SNPs, which are associated with the selection of parasite populations by ACT.
Sections du résumé
BACKGROUND
BACKGROUND
Pfcrt gene has been associated with chloroquine resistance and the pfmdr1 gene can alter malaria parasite susceptibility to lumefantrine, mefloquine, and chloroquine. In the absence of chloroquine (CQ) and extensive use of artemether-lumefantrine (AL) from 2004 to 2020 to treat uncomplicated falciparum malaria, pfcrt haplotype, and pfmdr1 single nucleotide polymorphisms (SNPs) were determined in two sites of West Ethiopia with a gradient of malaria transmission.
METHODS
METHODS
230 microscopically confirmed P. falciparum isolates were collected from Assosa (high transmission area) and Gida Ayana (low transmission area) sites, of which 225 of them tested positive by PCR. High-Resolution Melting Assay (HRM) was used to determine the prevalence of pfcrt haplotypes and pfmdr1 SNPs. Furthermore, the pfmdr1 gene copy number (CNV) was determined using real-time PCR. A P-value of less or equal to 0.05 was considered significant.
RESULTS
RESULTS
Of the 225 samples, 95.5%, 94.4%, 86.7%, 91.1%, and 94.2% were successfully genotyped with HRM for pfcrt haplotype, pfmdr1-86, pfmdr1-184, pfmdr1-1042 and pfmdr1-1246, respectively. The mutant pfcrt haplotypes were detected among 33.5% (52/155) and 80% (48/60) of isolates collected from the Assosa and Gida Ayana sites, respectively. Plasmodium falciparum with chloroquine-resistant haplotypes was more prevalent in the Gida Ayana area compared with the Assosa area (COR = 8.4, P = 0.00). Pfmdr1-N86Y wild type and 184F mutations were found in 79.8% (166/208) and 73.4% (146/199) samples, respectively. No single mutation was observed at the pfmdr1-1042 locus; however, 89.6% (190/212) of parasites in West Ethiopia carry the wild-type D1246Y variants. Eight pfmdr1 haplotypes at codons N86Y-Y184F-D1246Y were identified with the dominant NFD 61% (122/200). There was no difference in the distribution of pfmdr1 SNPs, haplotypes, and CNV between the two study sites (P > 0.05).
CONCLUSION
CONCLUSIONS
Plasmodium falciparum with the pfcrt wild-type haplotype was prevalent in high malaria transmission site than in low transmission area. The NFD haplotype was the predominant haplotype of the N86Y-Y184F-D1246Y. A continuous investigation is needed to closely monitor the changes in the pfmdr1 SNPs, which are associated with the selection of parasite populations by ACT.
Identifiants
pubmed: 37270589
doi: 10.1186/s12936-023-04602-6
pii: 10.1186/s12936-023-04602-6
pmc: PMC10239113
doi:
Substances chimiques
Antimalarials
0
N-formyl-13-dihydrocarminomycin
76634-96-3
Artemether, Lumefantrine Drug Combination
0
Artemether
C7D6T3H22J
Chloroquine
886U3H6UFF
Lumefantrine
F38R0JR742
Multidrug Resistance-Associated Proteins
0
Protozoan Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
171Informations de copyright
© 2023. The Author(s).
Références
Int J Parasitol Drugs Drug Resist. 2015 Jun 29;5(3):92-9
pubmed: 26236581
Malar J. 2015 May 19;14:208
pubmed: 25986047
Int J Parasitol Drugs Drug Resist. 2021 Apr;15:43-56
pubmed: 33556786
Sci Rep. 2022 Jan 11;12(1):517
pubmed: 35017593
Gene. 2020 Apr 30;736:144414
pubmed: 32006594
J Infect Dis. 2003 Jun 15;187(12):1870-5
pubmed: 12792863
Mol Microbiol. 2005 Aug;57(4):913-26
pubmed: 16091034
Nat Commun. 2022 Oct 26;13(1):6353
pubmed: 36289202
Mem Inst Oswaldo Cruz. 2012 Feb;107(1):129-34
pubmed: 22310546
Malar J. 2006 Jul 03;5:54
pubmed: 16817953
Front Genet. 2021 Jun 25;12:668574
pubmed: 34249090
Infect Drug Resist. 2018 Aug 28;11:1329-1338
pubmed: 30214253
PLoS Med. 2015 Mar 03;12(3):e1001788
pubmed: 25734259
Nat Commun. 2016 May 18;7:11553
pubmed: 27189525
Antimicrob Agents Chemother. 2011 Nov;55(11):5408-11
pubmed: 21896916
Proc Natl Acad Sci U S A. 2015 Sep 15;112(37):11672-7
pubmed: 26261345
Cold Spring Harb Perspect Med. 2017 Jul 5;7(7):
pubmed: 28289248
Nat Med. 2020 Oct;26(10):1602-1608
pubmed: 32747827
Malar J. 2014 Mar 27;13:120
pubmed: 24674605
Malar J. 2014 Oct 15;13:406
pubmed: 25318907
Malar J. 2022 Oct 7;21(1):286
pubmed: 36207750
Malar Res Treat. 2014;2014:950424
pubmed: 25506039
Antimicrob Agents Chemother. 2012 Jun;56(6):2976-86
pubmed: 22430961
BMC Res Notes. 2019 Apr 23;12(1):235
pubmed: 31014391
Sci Rep. 2015 Feb 06;5:8308
pubmed: 25655315
Infect Dis Poverty. 2018 Nov 05;7(1):103
pubmed: 30392470
Malar J. 2016 Feb 24;15:110
pubmed: 26911145
Antimicrob Agents Chemother. 2022 Sep 20;66(9):e0000222
pubmed: 35993723
Emerg Infect Dis. 2008 Oct;14(10):1637-40
pubmed: 18826834
BMJ Glob Health. 2018 Oct 19;3(5):e000999
pubmed: 30397515
Parasitol Res. 2019 Oct;118(10):3085-3089
pubmed: 31396714
Am J Trop Med Hyg. 2021 Jul 16;105(4):1093-1096
pubmed: 34270459
Int J Parasitol Drugs Drug Resist. 2019 Dec;11:8-12
pubmed: 31539706
Malar J. 2013 Oct 30;12:377
pubmed: 24172030
PLoS Negl Trop Dis. 2017 Jul 26;11(7):e0005806
pubmed: 28746333
Malar Res Treat. 2014;2014:614190
pubmed: 25506465
Biol Methods Protoc. 2020 May 02;5(1):bpaa009
pubmed: 32665976
Malar J. 2016 Nov 8;15(1):541
pubmed: 27825353
Malar Res Treat. 2018 May 02;2018:7071383
pubmed: 29854394
Mem Inst Oswaldo Cruz. 2004 Jun;99(4):389-92
pubmed: 15322628
Am J Trop Med Hyg. 2013 Mar;88(3):536-41
pubmed: 23382159
Am J Trop Med Hyg. 2007 Dec;77(6 Suppl):170-80
pubmed: 18165490
Int J Infect Dis. 2008 Nov;12(6):630-4
pubmed: 18926753
Trop Med Int Health. 2013 Jul;18(7):796-9
pubmed: 23621761
Elife. 2022 Jul 07;11:
pubmed: 35796430
Malar J. 2015 Jul 08;14:264
pubmed: 26152336
Malar J. 2009 Jan 12;8:11
pubmed: 19138391
Malar J. 2014 Jun 25;13:244
pubmed: 24964730